299 related articles for article (PubMed ID: 26801190)
1. Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.
Lieberknecht V; Junqueira SC; Cunha MP; Barbosa TA; de Souza LF; Coelho IS; Santos AR; Rodrigues AL; Dafré AL; Dutra RC
Mol Neurobiol; 2017 Mar; 54(2):1033-1045. PubMed ID: 26801190
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic Receptors as Neuroimmune Mediators in Experimental Autoimmune Encephalomyelitis.
Gonçalves ECD; Lieberknecht V; Horewicz VV; Rabelo BD; Felipetti FA; Rodrigues ALS; Martins DF; Dutra RC
Mol Neurobiol; 2021 Nov; 58(11):5971-5985. PubMed ID: 34432265
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
Li C; Guo Y; Xie W; Li X; Janokovic J; Le W
Neurochem Res; 2010 Oct; 35(10):1546-56. PubMed ID: 20635141
[TBL] [Abstract][Full Text] [Related]
4. Reinforcing properties of Pramipexole in normal and parkinsonian rats.
Engeln M; Ahmed SH; Vouillac C; Tison F; Bezard E; Fernagut PO
Neurobiol Dis; 2013 Jan; 49():79-86. PubMed ID: 22940424
[TBL] [Abstract][Full Text] [Related]
5. Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype.
Merlo S; Canonico PL; Sortino MA
Neuropharmacology; 2011 May; 60(6):892-900. PubMed ID: 21272591
[TBL] [Abstract][Full Text] [Related]
6. Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain.
Chernoloz O; El Mansari M; Blier P
J Psychiatry Neurosci; 2012 Feb; 37(2):113-21. PubMed ID: 22023785
[TBL] [Abstract][Full Text] [Related]
7. Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model.
Winner B; Desplats P; Hagl C; Klucken J; Aigner R; Ploetz S; Laemke J; Karl A; Aigner L; Masliah E; Buerger E; Winkler J
Exp Neurol; 2009 Oct; 219(2):543-52. PubMed ID: 19619535
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant-like effect of pramipexole in an inflammatory model of depression.
Lieberknecht V; Cunha MP; Junqueira SC; Coelho ID; de Souza LF; Dos Santos AR; Rodrigues AL; Dutra RC; Dafre AL
Behav Brain Res; 2017 Mar; 320():365-373. PubMed ID: 27825895
[TBL] [Abstract][Full Text] [Related]
9. Physical Exercise Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Peripheral Immune Response and Blood-Brain Barrier Disruption.
Souza PS; Gonçalves ED; Pedroso GS; Farias HR; Junqueira SC; Marcon R; Tuon T; Cola M; Silveira PCL; Santos AR; Calixto JB; Souza CT; de Pinho RA; Dutra RC
Mol Neurobiol; 2017 Aug; 54(6):4723-4737. PubMed ID: 27447807
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.
Du F; Li R; Huang Y; Li X; Le W
Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585
[TBL] [Abstract][Full Text] [Related]
11. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
Ling ZD; Robie HC; Tong CW; Carvey PM
J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
[TBL] [Abstract][Full Text] [Related]
12. Inosine, an Endogenous Purine Nucleoside, Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis: a Role for A2A Adenosine Receptor.
Junqueira SC; Dos Santos Coelho I; Lieberknecht V; Cunha MP; Calixto JB; Rodrigues ALS; Santos ARS; Dutra RC
Mol Neurobiol; 2017 Jul; 54(5):3271-3285. PubMed ID: 27130268
[TBL] [Abstract][Full Text] [Related]
13. Prolonged treatment with pramipexole promotes physical interaction of striatal dopamine D3 autoreceptors with dopamine transporters to reduce dopamine uptake.
Castro-Hernández J; Afonso-Oramas D; Cruz-Muros I; Salas-Hernández J; Barroso-Chinea P; Moratalla R; Millan MJ; González-Hernández T
Neurobiol Dis; 2015 Feb; 74():325-35. PubMed ID: 25511804
[TBL] [Abstract][Full Text] [Related]
14. The adverse effects of pramipexole on probability discounting are not reversed by acute D
Orrù M; Strathman HJ; Floris G; Scheggi S; Levant B; Bortolato M
Eur Neuropsychopharmacol; 2020 Mar; 32():104-119. PubMed ID: 31983530
[TBL] [Abstract][Full Text] [Related]
15. Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients.
Deutschländer A; la Fougère C; Boetzel K; Albert NL; Gildehaus FJ; Bartenstein P; Xiong G; Cumming P
Neuroimage Clin; 2016; 12():41-6. PubMed ID: 27408789
[TBL] [Abstract][Full Text] [Related]
16. Ulinastatin attenuates experimental autoimmune encephalomyelitis by enhancing anti-inflammatory responses.
Feng M; Shu Y; Yang Y; Zheng X; Li R; Wang Y; Dai Y; Qiu W; Lu Z; Hu X
Neurochem Int; 2014 Jan; 64():64-72. PubMed ID: 24274996
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats.
Breuer ME; Groenink L; Oosting RS; Buerger E; Korte M; Ferger B; Olivier B
Eur J Pharmacol; 2009 Aug; 616(1-3):134-40. PubMed ID: 19549514
[TBL] [Abstract][Full Text] [Related]
18. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.
Siuciak JA; Fujiwara RA
Psychopharmacology (Berl); 2004 Sep; 175(2):163-9. PubMed ID: 14985923
[TBL] [Abstract][Full Text] [Related]
19. Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist.
Camacho-Ochoa M; Walker EL; Evans DL; Piercey MF
Neurosci Lett; 1995 Aug; 196(1-2):97-100. PubMed ID: 7501268
[TBL] [Abstract][Full Text] [Related]
20. Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats.
Chang WL; Breier MR; Yang A; Swerdlow NR
Pharmacol Biochem Behav; 2011 Oct; 99(4):634-8. PubMed ID: 21683731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
